List of Excipients in Branded Drug VALPROIC

Generic Drugs Containing VALPROIC

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	valproic acid	0591-4012	GELATIN
Actavis Pharma Inc	valproic acid	0591-4012	GLYCERIN
Actavis Pharma Inc	valproic acid	0591-4012	PEANUT OIL

What are the Most Frequently-Used Excipients in VALPROIC?

# Of NDCs	Excipient
1	CORN OIL
1	FD&C BLUE NO. 1
10	GELATIN

Last updated: July 30, 2026

Valproic Acid Excipient Strategy and Commercial Opportunities: What to Know for Formulation, IP Barriers, and Generic Launch Risk

Valproic acid products compete on (1) bioavailability consistency, (2) GI tolerability and dose flexibility, and (3) patient adherence driven by dosing frequency and taste/handling. From a commercial standpoint, the highest-value formulation opportunities sit in extended-release (ER), sprinkle/granule presentations for pediatrics, and fixed-dose combinations where solubility and stability constraints can differentiate. Patent and Orange Book protection typically centers on formulation composition, release profiles, particle/crystal/physical forms, and manufacturing methods more than the excipient “type” alone. Still, excipient selection can create IP and regulatory defensibility through documented control of dissolution, permeability, and stability.

What excipients control valproic acid absorption and GI tolerability?

Valproic acid’s absorption is sensitive to drug release rate, solubilization environment, and local GI exposure. Formulation excipients are therefore used to control:

• Dissolution and release kinetics (especially for delayed/ER dosage forms)
• Viscosity and dispersion for oral liquids and suspensions
• Stability in liquid and semi-solid systems
• Taste masking and patient acceptability for pediatric sprinkle and liquid dosing

Which excipient classes are used in valproate products by dosage form?

Oral capsules/tablets (IR and delayed):

• Cellulose derivatives and film formers: support tablet compression and coating integrity
• Polymer matrices and hydrophilic gel-forming polymers (for ER)
• pH microenvironment modifiers (where relevant to coated products)
• Lubricants and disintegrants for reproducible breakup and dissolution

ER formulations (matrix or coated beads/spheres):

• Hydrophilic polymers (ER rate control through swelling/gel layer)
• Porosity-forming agents (control water ingress)
• Plasticizers and film formers (mechanical integrity)
• Anti-tacking and flow aids (improve manufacturing scale-up and batch uniformity)

Oral liquids (solutions/syrups) and pediatric suspensions:

• Solubilizers/co-solvents for valproate salt solubility management
• Viscosity modifiers to prevent settling and improve dosing accuracy
• Preservatives and antioxidants for chemical stability
• Sweeteners and flavor systems for adherence

Sprinkles/granules (pediatric):

• Controlled-release beads or granules with protective coatings
• Film formers that withstand mixing and gastric passage
• Anti-sticking agents for handling and uniform dose delivery

How do excipient choices affect bioequivalence risk for generic valproic acid?

Generic risk often arises when ER or delayed-release products depend on excipients that govern:

• Dissolution profile shape across the dosing interval
• Food effect magnitude via release lag time and gel formation
• Batch-to-batch uniformity of polymer hydration and drug distribution
• Manufacturing sensitivity (coating thickness, granule size distribution, drying conditions)

In practice, excipient “substitution” is not interchangeable unless the applicant can prove the release mechanism is equivalent under relevant conditions.

What patents protect valproic acid formulations and excipient systems?

Patent coverage for valproic acid products usually focuses on:

• Compositions (drug plus specified excipients within defined ranges)
• Controlled-release mechanisms (polymer systems, ratios, and processing)
• Methods of preparation (coating/granulation steps that define performance)
• Physical form and particle engineering where relevant (granule/crystal properties)

Excipient strategies can intersect with IP when the claims specify:

• particular polymers (or defined polymer blends)
• specific release-controlling excipient architectures
• processing parameters that create a defined dissolution profile

How to map excipient strategy to typical claim types

For formulation entrants, the practical IP landscape can be grouped into five claim buckets:

1. Composition claims
   Specified valproate drug form plus defined excipients (e.g., ER polymer + plasticizer + rate-controlling components).

2. Release profile claims
   Claims tied to a dissolution pattern (e.g., release at defined % at defined times).

3. Coating and bead/granule structure claims
   Multi-layer coating, bead cores, seal coats, porosity.

4. Method claims
   Wet granulation, coating, drying, compression, and curing conditions that influence performance.

5. Method-of-manufacture validation claims
   Tight process parameters that become effectively difficult to “design around” without performance testing.

Do excipient-only changes create freedom-to-operate?

Excipient swaps can reduce infringement if the claims are limited to a narrow excipient set or specific ranges. If claims are broader (for example, “an ER polymer system comprising…” with functional recitations), design-around can be harder. Commercial teams typically treat excipient substitution as a function of both claim language and release mechanism equivalence under FDA bioequivalence standards.

When does valproic acid lose exclusivity in the US for branded products?

Valproic acid’s exclusivity timeline depends on the specific NDA or ANDA reference product, dosage form, and whether the branded product relied on:

• New chemical entity (NCE) exclusivity (if applicable)
• 3-year exclusivity tied to changes (formulation, route, indication)
• Patent expiration and potential pediatric exclusivity extensions
• Orange Book listing status for the exact dosage form

Why excipient strategy matters even after patent expiration

Even post-expiry, exclusivity can persist at the dosage form level through:

• additional patents listed in the Orange Book
• exclusivity tied to specific supplements
• REMS or manufacturing-linked constraints

Excipient strategy is also critical for challenger differentiation. If branded ER products rely on specific matrix and polymer hydration behavior, generic launches that match only active release endpoints may still face:

• formulation development delays
• slower market uptake if interchangeability is questioned by payers and clinicians

What is the Orange Book status of valproic acid products and how many patents cover them?

Orange Book coverage must be assessed per:

• active moiety (valproic acid)
• salt (valproate sodium, divalproex sodium)
• dosage form (IR tablets vs delayed vs ER)
• strength (often relevant for listed patents and manufacturing specifics)

A complete Orange Book audit is usually the first step in evaluating:

• number of listed patents per product
• patent expiration dates
• which patents are formulation, process, or method-of-use
• which patents are susceptible to Paragraph IV

What to prioritize in the Orange Book for excipient strategy

For formulation and commercialization planning, teams typically prioritize:

• formulation and controlled-release patents (most sensitive to excipient choices)
• process patents that may be implicated by coating or granulation changes
• pediatric-related listed patents that can extend time-to-market
• patents that specify dissolution criteria (directly tied to excipient architecture)

Which valproic acid generic opportunities are driven by Paragraph IV challenges?

Paragraph IV strategy is usually best aligned with assets where:

• branded patents are expiring soon
• multiple formulation/process patents are clustered but some are weaker or easier to design around
• an applicant can demonstrate bioequivalence with a different excipient system while meeting dissolution and pharmacokinetic targets

Where excipient strategy creates a competitive edge in Paragraph IV

Two commercial pathways dominate:

1. Mechanism-equivalent ER/delayed-release using different excipients
   Goal: match the branded release profile without using the claimed polymer blend or specific coating architecture.

2. IR or delayed-to-ER lifecycle extension
   If a branded product’s value is driven by ER adherence, excipient-enabled engineering can target interchangeability at the patient and payer level, even when generic is not a direct excipient clone.

Settlement-driven timing risk

Paragraph IV litigation often ends in:

• 30-month stay expirations after which launch proceeds
• settlement-triggered earlier launch dates for certain filers
• exclusivity carve-outs for authorized generics

Excipient strategy still matters because settlements often specify product performance targets, manufacturing location constraints, and labeling requirements that can narrow formulation freedom.

How does valproic acid excipient strategy differ for ER vs delayed-release vs IR?

ER: excipient architecture as the product identity

ER formulation performance is typically governed by:

• hydrophilic polymer swelling kinetics
• diffusion pathway formation in matrix or coating systems
• porosity control and water ingress rates

Excipient changes that alter gel thickness, viscosity, or diffusion can shift the release curve and trigger failed dissolution specifications, even if the active ingredient and strength match.

Delayed-release: site and lag time control

Delayed-release systems focus on lag time and protection from early dissolution. Excipients supporting enteric coatings, buffering microenvironments, or protective barriers can be critical.

IR: patient tolerability and dose flexibility

IR products rely more on:

• disintegrants for consistent dissolution
• solubilizers for oral liquids
• viscosity control to improve dosing accuracy
• taste and handling for pediatrics

What formulation opportunities exist for pediatrics: sprinkle, granules, and oral liquids?

Pediatric commercial opportunity concentrates on presentations that improve:

• dosing precision
• acceptance (taste, viscosity, aftertaste)
• adherence with flexible administration

Sprinkle/granule platforms

Sprinkle platforms are commercially attractive because they:

• allow dose titration
• can reduce barriers for caregiver administration
• support controlled-release behavior via bead/granule coatings

Excipient strategy focuses on:

• anti-stick agents and handling aids
• coating robustness (stability during mixing)
• minimal interaction with common food textures

Oral liquid opportunities

Oral liquids remain relevant where:

• patients need dose titration by mL
• administration to patients with swallowing challenges is required

Excipient strategy centers on:

• stability (chemical degradation management)
• solubilization and uniformity (avoid settling and assay drift)
• palatability and viscosity control (reduce variability in dosing)

Can valproic acid fixed-dose combinations create new commercial value?

Fixed-dose combinations are attractive because they can:

• improve adherence by reducing pill burden
• open payer coverage pathways through regimen-based prescribing

Excipient strategy for combinations is challenging due to:

• potential incompatibilities between actives
• differing dissolution needs and release profiles
• stability constraints under heat, humidity, and light

From an IP and development standpoint, combination entrants often seek:

• formulation patents for the combination composition and release behavior
• process patents tied to maintaining stability and meeting dissolution specs

How strong is the patent estate for valproic acid drug products by formulation type?

A practical strength view for investors and litigators uses three dimensions:

• number of active Orange Book patents remaining
• density of formulation/process patents per dosage form
• claim specificity that narrows design-around space

ER and delayed-release generally carry the densest formulation IP

Controlled-release dosage forms tend to have more:

• composition and release-profile patents
• method-of-manufacture patents for coating/granulation
• listed patents that support specific performance criteria

IR and oral liquids may have fewer, but stability-driven claims can still be meaningful

Oral liquids often have patents tied to:

• stability-enhancing excipient combinations
• pH, antioxidant, and preservative systems
• shelf-life and packaging stability constraints

Which companies are best positioned to commercialize new valproic acid formulations or generics?

Commercial positioning is typically led by:

• large generic manufacturers with ER/delayed-release development capacity
• contract development and manufacturing organizations (CDMOs) with coating and granulation platforms
• brand holders defending controlled-release performance through patent thickets and settlements

Market winners usually have:

• validated dissolution and bioequivalence tooling
• scale-up capability for polymer coating and controlled-release architectures
• strong regulatory operations for ANDA submissions and labeling alignment

What generic entry risks exist for valproic acid based on excipient and dissolution constraints?

Key entry risks include:

• Bioequivalence failure due to release profile mismatch (especially ER)
• Dissolution method sensitivity where minor excipient changes alter performance
• Stability drift driven by excipient moisture interactions or container compatibility
• Manufacturing variability in polymer hydration or coating thickness distribution
• Litigation exposure where design-around excipient choices still fall within functional claim scope

What manufacturing and supply-chain choices matter for excipient strategy in valproic acid?

Excipient procurement and manufacturing controls affect both:

• regulatory compliance (consistency, specification control)
• product performance (batch uniformity)

The commercialization-critical manufacturing parameters include:

• drying and granulation conditions that determine porosity and hydration
• coating pan or fluid-bed process controls that govern thickness and uniformity
• compression parameters for tablets impacting disintegration timing
• fill-finish constraints for liquids (viscosity, filterability, container compatibility)

Key Takeaways

• Valproic acid formulation value is driven by controlled release performance, GI tolerability, stability, and dosing convenience, not by broad excipient “brand names.”
• The highest commercial opportunity typically sits in ER and pediatric-friendly presentations (sprinkles/granules and oral liquids) because excipient architecture directly affects dissolution, bioequivalence risk, and clinician/payer preference.
• Patent protection is most relevant for controlled-release and stability-linked excipient systems, where claims often specify polymer blends, coating architectures, and defined release profiles.
• Generic entry risk is concentrated in ER/delayed-release release matching and in stability/manufacturing sensitivity tied to excipient behavior.
• Paragraph IV and settlement dynamics can open windows, but excipient strategy remains a gating factor for manufacturing scale-up and regulatory defensibility.

FAQs

1. What excipients are most likely to change the dissolution profile of valproic acid ER products?
Hydrophilic ER polymers and porosity-forming/gel-layer modifiers that control water ingress and diffusion are most consequential.

2. How do patient populations shape valproic acid formulation strategy?
Pediatric and adherence-focused populations favor sprinkle/granules and dosing flexibility, while seizure control consistency favors ER/delayed-release performance.

3. Does changing valproate salt form affect excipient strategy?
Yes. Salt form impacts solubility, hygroscopicity, and stability, which drives different solubilizers, buffering, and moisture-control excipient choices.

4. What formulation attributes are most likely to be scrutinized in a valproic acid bioequivalence submission?
ER/delayed-release dissolution profile shape across timepoints, food-effect behavior, and variability between lots.

5. Where do excipient design-around efforts most often fail in valproic acid litigation risk assessments?
When functional claim language ties protection to release behavior and polymer system function rather than to specific excipient identities.

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. (n.d.). Abbreviated New Drug Application (ANDA) Submissions for Generic Drugs. U.S. Food and Drug Administration.
3. FDA. (n.d.). Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Spray, Inhalation Aerosols, and/or Transdermal Delivery. U.S. Food and Drug Administration.
4. FDA. (n.d.). Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations. U.S. Food and Drug Administration.